Previous 10 | Next 10 |
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights t...
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
The following slide deck was published by Myriad Genetics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Myriad Genetics, Inc. 2022 Q1 - Results - Earnings Call Presentation
Myriad Genetics, Inc. (MYGN) Q1 2022 Earnings Conference Call May 5, 2022 04:30 PM ET Company Participants Nathan Smith - Senior Vice President, Investor Relations Paul Diaz - President & Chief Executive Officer Bryan Riggsbee - Chief Financial Officer Nicole Lambert - Chief Operating Off...
Myriad Genetics press release (NASDAQ:MYGN): Q1 Non-GAAP EPS of -$0.03 beats by $0.06. Revenue of $164.9M (-4.7% Y/Y) beats by $8.81M. FY22 Outlook: Revenue guidance of $6700m-$700M vs consensus of $685.41m; Adj EPS of $0.00-$0.20 vs consensus of $0.08 For further details see: Myriad Ge...
Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year D iluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the firs...
SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of Am...
Myriad Genetics (NASDAQ:MYGN) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.09 (-50.0% Y/Y) and the consensus Revenue Estimate is $156.09M (-9.8% Y/Y). Over the last 2 years, MYGN has beaten EPS estimates 75% of the ti...
Precise™ Liquid Biopsy will provide insights on circulating tumor DNA in the blood to help guide cancer treatment decisions SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, t...
SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings wil...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the...
2024-04-23 07:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...